Paula Soteropoulos

Paula Soteropoulos joined 5AM Ventures in 2020 and serves as a Strategic Advisor. Ms. Soteropoulos has more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L accountability, company building and organizational development. Her leadership throughout her career spans a broad range of therapeutic areas, including rare disease, cardiovascular and metabolism, infectious disease, renal, and transplant and oncology. She is the Executive Chairman of NewCo, Ensoma, working with the founding team to launch the company, establish strategic priorities and build-out the leadership team. She also serves on the board of directors of uniQure, a leader in gene therapy and most recently served as the CEO and a member of the board of directors of rare disease therapeutic developer Akcea Therapeutics. Ms. Soteropoulos was the founding President and CEO in 2015 and led the company through its IPO on NASDAQ in 2017, as well as significant growth: employing over 270 staff in thirteen countries, six drugs in its portfolio with 2 rare disease drug approvals and commercial launches. Prior, she served as Senior Vice President and General Manager, Cardiometabolic and Rare Disease Businesses & Strategic Alliances at Moderna Therapeutics and worked for over 20 years at Genzyme Corporation, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos has served on the Advisory Board of the Tufts University Chemical and Biological Engineering Department since 2005. She has B.S. and Master’s degrees in Chemical and Biochemical Engineering from Tufts University and an executive management certificate from the Darden School of Business, University of Virginia. Ms. Soteropoulos is based in the Boston, MA office.